A further bypass signaling mechanism leading to MEK-inhibitor resistance is due to MEK-inhibitor-induced reduction of proteolytic shedding of membrane receptors, leading to surface RTK accumulation, with activation of other pathways supporting tumor growth, such as JNK–cJUN and AKT [191]. The gene discussed is MAP2K7; the disease is neoplasm.